Cancer Council Queensland has announced a $2 million investment in cancer research projects across Queensland over two years, as it reveals its 2018/19 research grant recipients.
10 researchers* from leading institutions will receive $200,000 over two years toward their projects, to improve treatment options and quality of life for Queenslanders diagnosed with cancer.
The research grants will fund world-leading studies into various areas including immunotherapy, new ways to treat acute myeloid leukaemia, melanoma, breast cancer and lung cancer, and more.
Cancer Council Queensland CEO Ms Chris McMillan said the charity was proud to fund research projects that had the potential to save many lives.
“More Queenslanders were surviving cancer than any other time in history, thanks to advances in cancer research and treatment options, and our vision is for that to continue,” Ms McMillan said.
“Investment in innovative, cutting-edge, ground-breaking research in Queensland is vital to improve survival rates for all types of cancer.
“Cancer Council Queensland proudly funds more cancer research than any other independent community-based charity in the state.
“We recognise the urgent need for greater investment into local research projects that will influence clinical trials and treatments for Queenslanders diagnosed.
“Congratulations to our grant recipients – we are excited to see the outcomes of these research grants over time, and give hope to more than 27,000 Queenslanders diagnosed with cancer every year.”
More than 27,000 Queenslanders are diagnosed with cancer each year, and about 8700 die from the disease.
More information about Cancer Council Queensland is available on 13 11 20 or cancerqld.org.au.
*CCQ Project Grants 2018/19
| Name | Institution | Project Title |
| Prof Riccardo Dolcetti | The University of Queensland | Improved antigen-specific immunotherapy for cutaneous malignant melanoma |
| Prof Gregory Monteith | The University of Queensland | Pharmacological targeting of an adaptive breast cancer cell survival pathway as a novel treatment for breast cancer: Constitutive Ca2+ influx mechanisms in triple negative breast cancer cells |
| Dr David Fielding | The University of Queensland | Streamlining lung cancer diagnosis through genomic testing of cytology smears |
| Prof Paul Alewood | The University of Queensland | Development of oxytocin receptor specific tracers for improved breast cancer management |
| Prof Brian Gabrielli | Mater Research – The University of Queensland | Preclinical development of combinations with CHK1 inhibitors in melanoma and lung cancer |
| Prof Jean-Pierre Levesque | Mater Research – The University of Queensland | Colony-stimulating factor 1 receptor tyrosine kinase, a new target to treat acute myeloid leukaemia |
| Dr Kate Gartlan | QIMR Berghofer Medical Research Institute | Characterising IL-5 mediated suppression of alloimmunity |
| Prof Mark Smyth | QIMR Berghofer Medical Research Institute | Inhibiting ILC1 formation in cancer |
| Associate Prof Kelli MacDonald | QIMR Berghofer Medical Research Institute | Analysis of pathogenic macrophage differentiation and function in chronic GVHD |
| Dr Jill Larsen | QIMR Berghofer Medical Research Institute | Identifying ‘cooperative’ mutations in non-small cell lung carcinoma that facilitate lung carcinogenesis |
For more information or interviews, please contact: